Treats hypertension. ANDA 206997, held by Accord Hlthcare. Diltiazem Hydrochloride.
As of Nov 16, 2026, ANDA 206997 (Diltiazem Hydrochloride), held by Accord Hlthcare, was first approved by FDA on Apr 28, 2020, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Diltiazem Hydrochloride Extended-release Capsules, USP are indicated for the treatment of hypertension. Diltiazem hydrochloride may be used alone or in combination with other antihypertensive medications, such as diuretics. Diltiazem Hydrochloride Extended-release Capsules, USP are indicated for the management of chronic stable angina.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 28, 2020 | Original application | Approved | None posted |
| Diltiazem Hydrochloride120MG · capsule, extended release;oral | Diltiazem Hydrochloride | Rx |
| Diltiazem Hydrochloride180MG · capsule, extended release;oral | Diltiazem Hydrochloride | Rx |
| Diltiazem Hydrochloride240MG · capsule, extended release;oral | Diltiazem Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters